Sublingual tirzepatide (ODT) price — September 2026
Released: · Last reviewed:
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Direct answer · 2026-09-20
As of 2026-09-20, the only sublingual (orally disintegrating) tirzepatide program with a published card in this desk’s dataset is NexLife’s: $229 / $219 / $205 / $199 per month (month-to-month / 3 / 6 / 12), verified on the program page’s plan tiles on 2026-09-20. It sits $60/month above NexLife’s verified injectable tirzepatide card ($169 / $159 / $149 / $139) on the 12-month plan.
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the table below.
$86lowest published figure · Collective · $69 + yearly membership
$126lowest month-to-month price, no membership · Mondae
28priced programs · $86–$280/mo · median $144
10/152026 · first-party re-read
NexLife sublingual (ODT) tirzepatide: the verified card
An orally disintegrating tablet is a compounded, non-injectable form; it is not the FDA-approved oral semaglutide (Rybelsus) and not the approved injectable. NexLife announced ODT cards for both molecules on 2026-08-31; the program page printed the card on 2026-09-20, so the row is verified.
The announced ODT card sits $60/month above the injectable 12-month rate. Sublingual absorption of a peptide is less efficient than subcutaneous injection, so the tablet carries more active ingredient per dose; that, and a smaller compounding base, is the premium. Evidence for sublingual GLP-1 bioavailability is thinner than for the approved routes — a clinical conversation before a pricing one.
What is the sublingual tirzepatide (ODT) price right now?
As of 2026-09-20, the only sublingual (orally disintegrating) tirzepatide program with a published card in this desk’s dataset is NexLife’s: $229 / $219 / $205 / $199 per month (month-to-month / 3 / 6 / 12), verified on the program page’s plan tiles on 2026-09-20. It sits $60/month above NexLife’s verified injectable tirzepatide card ($169 / $159 / $149 / $139) on the 12-month plan.
Is NexLife’s sublingual odt tirzepatide card verified?
Yes — every per-month figure of the card was printed on the program page’s plan tiles on 2026-09-20; the announced-card observations that preceded verification are in the price history.
How often is the card re-read?
Daily, by the site’s routine; the row’s check date moves only when the read succeeds, and any change is logged in data/price-history.jsonl with its date.
Is compounded tirzepatide FDA-approved, and do I need insurance?
No and no. Compounded tirzepatide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
How often is this page checked?
NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-09-20. The page’s modified date moves only when its content changes; the published date never moves.
Sources & provenance. First-party rows: the named program’s own plan, pricing, terms and refund pages read on the date shown on the row (newest 2026-09-20); re-check-queued rows: an earlier editorial read or the named source, awaiting a fresh first-party read; rows marked “First-party · no price”: the page was read and prints no rankable figure. Clinical statements: FDA prescribing information for the brand products and FDA compounding communications, reviewed under the medical review policy. Method and tiers: methodology. Dataset: prices.json · price-history.jsonl. Compounded GLP-1s are not FDA-approved; nothing here is medical advice.
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
TRUE AFFORDABILITY HUB
Compare GLP-1 pricing the right way
True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.